Session Content References

There are many ongoing advances in patient safety in the context of immunotherapy, targeted therapy, surgery and RT for treatments for recurrent HNSCC. Failure to stay informed leads to lower quality of care for these challenging care paradigms by practicing clinicians.

It is imperative that our HNSCC medical care team across specialties remain current in the state-of-the-art techniques (Knowledge). There are many ongoing advances in patient safety in the context of immunotherapy, targeted therapy, surgery and RT for treatments for recurrent HNSCC (knowledge). Failure to stay informed leads to lower quality of care for these challenging care paradigms by practicing clinicians (competence). This meeting provides attendees the opportunity to gain exposure to the latest science, trials and best practices (performance). This panel is comprised of the leading experts in each of these arenas.  They will share the latest research and practices along with practical case vignettes.

Potential Challenges/Barriers to Change:

1. Lack of resources (financial)
2. Lack of access

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Become exposed to the latest trials and research findings to change their practice patterns to support best practices in immunotherapy, for treatments for recurrent HNSCC.
2. Become exposed to the latest trials and research findings to change their practice patterns to support best practices in targeted therapy, for treatments for recurrent HNSCC.
3. Become exposed to the latest trials and research findings to change their practice patterns to support best practices in surgical approaches for recurrent HNSCC.
4. Become exposed to the latest trials and research findings to change their practice patterns to support best practices in radiation therapy, for treatments for recurrent HNSCCC.

References:

1. https://www.asia.elsevierhealth.com/multidisciplinary-approach-to-head-and-neck-cancer-an-issue-of-otolaryngologic-clinics-of-north-america-9780323532495.html
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349813/

There are many new treatments and considerations of treatment of advanced cutaneous squamous cell carcinoma. A multidisciplinary approach is often needed, in conjunction with standard guidelines and recommendations, to provide the safest, most practical, and up to date treatment available.

It is important for medical practitioners to recognize treatment options available and the current standards tailored to an individual patient’s needs and clinical presentations, and to expand upon the learning base to apply to practice standards to this patient population.

Advanced cutaneous SCC is becoming more prevalent, with more aggressive disease noted. There are now many different acceptable approaches to treating this disease, involving multidisciplinary expertise, including that of Dermatology (including Mohs surgeons), Surgeons (head and neck, plastics and reconstruction), radiation oncologists, and medical oncologists. This session will serve to present the most current and up to date evidence for treatment as well as provide real-world perspectives from leaders in the field from a variety of disciplines.

Potential Challenges/Barriers to Change: Multidisciplinary care – if in rural or otherwise isolated areas of practice where access to different specialists may be limited

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Recognize clinical scenarios constituting advanced cSCC.
2. Identify patients who would benefit from a multidisciplinary approach to treatment planning.
3. Become more aware of current accepted practice patterns.
4. Become exposed to the latest trials and research findings to change their practice patterns to support best practices in radiation therapy, for treatments for recurrent HNSCCC.

References:

1. NCCN Guidelines Squamous Cell Skin Cancer, Version 1.2024
2. ASTRO Clinical Practice Guideline, 2019
3. N Engl J Med; 387:1557-1568

There are many ongoing advances in neoadjuvant immunotherapy in curative-intent head and neck cancer, yet optimal incorporation and biomarkers remain undefined. There is an urgent need to keep medical oncologists, head and neck surgeons, and radiation oncologists who treat head and neck cancer informed regarding emerging data regarding neoadjuvant immunotherapy in this setting.

This educational activity will discuss the evolving role of neoadjuvant immunotherapy in head and neck cancer. The role of predictive biomarkers in the context of neoadjuvant immunotherapy in resectable head and neck cancer will be discussed. Ongoing clinical trials evaluating neoadjuvant immunotherapy will also be addressed.

Potential Challenges/Barriers to Change:

1. Rapidly emerging data
2. Patient selection
3. Further research needed

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Understand the evolving literature regarding the role of immunotherapy in curative intent head and neck cancer.
2. Characterize biomarkers in setting of neoadjuvant immunotherapy.
3. Be aware of ongoing prospective trial efforts to evaluate neoadjuvant immunotherapy.

References:

1. Machiels et al. ESMO 2022
2. Lee et al Lancet 2021.
3. Uppaluri et al. CCR 2020.

Novel immunotherapeutic approaches combined with conventional therapies such as surgery, radiation and immunotherapy are increasingly being used in head and neck squamous cell carcinomas. Failure to stay informed leads to unawareness of novel paradigms that are being developed and ultimately to the direction in which treatment paradigms may be transitioning.

It is imperative that Head and Neck Cancer surgical, medical and radiation oncologists remain aware of the novel therapeutic paradigms and emerging innovative paradigms for the treatment of advanced head and neck cancers.

This activity seeks to review innovative clinical trials in the treatment of head and neck cancers from a radiation, surgical and systemic therapy perspective. These trials have novel translational components that may spearhead the next generation of novel clinical trials in these diseases. Further, this session will also provide information regarding the FDA’s Project Optimus which seeks to optimize dose delivery and duration of cancer therapeutics which will also be critical in the setting of novel clinical trials.

Potential Challenges/Barriers to Change:

1. Lack of resources – developing and coordinating these translational studies requires multidisciplinary collaboration and external funding.
2. Lack of knowledge/expertise – given these trials are multidisciplinary in nature, they often require collaboration with basic scientists and clinicians with expertise in bridging the gaps between the lab and clinic.

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Describe changes related to neoadjuvant radiotherapy for head and neck squamous cancers.
2. Describe changes related to neoadjuvant immunotherapeutics for head and neck squamous cancers.
3. Understand viral targeting as a systemic therapeutic approach for HPV-related cancers.

References:

1. Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022 Sep 15;132(18):e161400. doi: 10.1172/JCI161400. Erratum in: J Clin Invest. 2023 Jun 1;133(11): PMID: 35727629; PMCID: PMC9479764.
2. Runnels J, Bloom JR, Hsieh K, Dickstein DR, Shi Y, Jones BM, Lehrer EJ, Bakst RL. Combining Radiotherapy and Immunotherapy in Head and Neck Cancer. Biomedicines. 2023 Jul 25;11(8):2097. doi: 10.3390/biomedicines11082097. PMID: 37626594; PMCID: PMC10452591.
3. Saba NF, Pamulapati S, Patel B, Mody M, Strojan P, Takes R, Mäkitie AA, Cohen O, Pace-Asciak P, Vermorken JB, Bradford C, Forastiere A, Teng Y, Wieland A, Ferlito A. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers (Basel). 2023 Mar 24;15(7):1959. doi: 10.3390/cancers15071959. PMID: 37046621; PMCID: PMC10092986.

The treatment of early and advanced thyroid cancer is rapidly changing due to developments in targeted drug therapy and new surgical and noninvasive approaches. This session will familiarize the learner with new agents and techniques and their appropriate place in the treatment algorithms.

• The oncologist must be aware of new targeted agents in the treatment of advanced thyroid cancer and understand their appropriate use.
• The surgical oncologist should understand the risk to the recurrent laryngeal nerve in advanced thyroid cancer surgery and know how to manage possible invasion.
• The surgical oncologist must be aware of new noninvasive approaches to microcarcinoma and know their appropriate application.

The treatment of early and advanced thyroid cancer is rapidly changing due to developments in targeted drug therapy and new surgical and minimally invasive approaches. This session will familiarize the learner with new targeted agents and their appropriate place in the treatment algorithms. It will also explore nuances in surgical therapy, including management of the recurrent laryngeal nerve in invasive disease, and the new technique of radiofrequency ablation therapy for microcarcinomas.

Potential Challenges/Barriers to Change:

1. Lack of insurance coverage of RFA for thyroid nodule treatment
2. Lack of nerve monitoring equipment in the operating room
3. Lack of medical oncology expertise in thyroid cancer in certain communities

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Outline the management strategies of thyroid microcarcinoma, including the use of radiofrequency ablation therapy.
2. Identify the appropriate indications and drugs for the treatment of thyroid cancer with RET mutations.
3. Describe the use of neoadjuvant targeted therapy and surgery for advanced thyroid cancer.

References:

1. 2022 Consensus Statement on Minimally Invasive Procedures for Benign and Malignant Thyroid Lesions, AACE
2. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment, 2022
3. Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement, 2018

In the surgical management of parotid cancer, there is heterogeneity of extent of surgery for the primary tumor and involved and at-risk cervical lymphatics. By understanding the available evidence for the management of parotid cancer, practicing clinicians will be able to more appropriately offer the right level of surgical care.

Following surgical resection of salivary cancer, there are instances where providing adjuvant radiation therapy can improve disease control and/or survival. Failure to stay informed of these indications may lead to providers over or under recommending the use of adjuvant radiation and therefore compromising the quality of their cancer treatment.

There are ongoing advances in the use of targeted systemic therapy in the management of certain salivary cancers. Recognizing indications for when tumor sequencing and targeted systemic therapy should be considered will allow treating doctors to provide their patients with the highest quality multidisciplinary care.

It is important for practicing head and neck surgeons to remain current on the extent of surgery that is appropriate for management of salivary cancers based on their clinical stage and histopathology.

It is critical that radiation oncologists recognize indications for adjuvant radiation therapy as well as the potential use of definitive non-surgical therapy in the management of certain salivary cancers. This case-based panel will provide information on the indications for adjuvant radiation therapy in the management of salivary cancer and will discuss its use in the definitive setting.

The use of targeted systemic therapy is showing promise in certain salivary cancers. This panel will outline indications for when multidisciplinary teams should consider the use of systemic therapy in certain advanced, recurrent and/or metastatic salivary cancers.

This case-based panel will outline the multidisciplinary approach to patients with salivary cancer. Perspective will be provided by experts in the field on topics such as extent of primary tumor surgery and management of cervical lymphatics, as well as indications for adjuvant radiation therapy and the use of targeted therapy. This session will outline the available evidence on these topics and also allow for open discussion on these and other controversial topics within the field of salivary cancer management.

Potential Challenges/Barriers to Change:

1. Surgical oncologist may lack the understanding of the extent of surgery needed to properly manage salivary cancer.
2. Radiation oncologists may not have adequate experience or clinical volume when managing salivary cancers to best determine the proper approach to adjuvant radiotherapy in the patients.
3. Practicing medical oncologists may not have sufficient knowledge and experience in the use of targeted/systemic therapy for patients with recurrent/metastatic salivary cancers.

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. The learner will be able to better outline the extent of surgery needed for the primary tumor and involved and at-risk cervical lymphatics following this panel.
2. The learner will be able to describe indications for adjuvant radiotherapy in the management of salivary cancer.
3. The learner will understand the evolving role of targeted therapy in the management of salivary cancer.

References:

1. Zenga J, Parikh AS, Emerick KS, et al: Close margins and adjuvant radiotherapy in acinic cell carcinoma of the parotid gland. JAMA Otolaryngol Head Neck Surg 144:1011-1016, 2018.
2. Wang YL, Li DS, Gan HL, et al: Predictive index for lymph node management of major salivary gland cancer. Laryngoscope 122:1497-1506, 2012.
3. Lee A, Givi B, Osborn VW, et al: Patterns of care and survival of adjuvant radiation for major salivary adenoid cystic carcinoma. Laryngoscope 127:2057-2062, 2017.
4. Kurzrock R, Bowles DW, Kang H, et al: Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study. Ann Oncol 31:412-421, 2020.

The gaps in practice include the proper integration of new data with existing trials and practices in viral-driven head and neck cancers. There is also a lack of standardization and uniform adaptation of de-escalation trials, as well as barriers to the broader adaptation of these strategies in clinical practice.

There is a need for a deeper understanding of molecular profiling methods across different treatment stages and the application of personalized response monitoring and treatment adaptation based on recent trials.

Potential Challenges/Barriers to Change:

1. Lack of insurance coverage of certain new drugs.
2. Unwillingness to change institution-specific practices to reflect new evidence.
3. Lack of multi-disciplinary consensus regarding changes of practices.
4. Lack of access to specific tests/assays.

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Provide attendees with an integrated understanding of the latest and ongoing trials of NPC and to foster evidence-based approaches in the treatment of locally advanced and metastatic NPC.
2. Understand methodologies for molecular profiling spanning pre-treatment, on-treatment, and post-treatment responses for NPC. Explore clinical trials focusing on personalized response monitoring and subsequent treatment adaptation.
3. Understand varying types and mechanisms of therapeutic HPV vaccines, as well as ongoing and future trials of viral therapeutic vaccines. Recognize optimal strategies for trial design and clinical implementation.
4. Summarize both completed and ongoing HPV de-escalation trials, identify barriers to adoption of de-escalation strategies, and synthesize practical considerations.

References:

1. Noninvasive biopsies may be faster and more effective for diagnosing HPV-associated head and neck cancer. Fillon M. CA Cancer J Clin. 2022 May;72(3):200-201.
2. Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. (ASCO 2023).
3. Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial (ASCO 2023).
4. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) (ASCO 2023).

There is an urgent and pressing need to understand these issues for patients who are treated and cured of their head and neck cancers but have to live with the long-term consequences of their aggressive treatments which include combinations of surgery, radiation and chemotherapy. This session will highlight the challenges faced by head and neck cancer patients who undergo surgery, the challenges for head and neck cancer survivors, the elements of a successful survivorship program and the financial toxicity faced by these patients.

Knowledge regarding the body image distress in head and neck cancer survivors, elements of a successful survivorship program and financial toxicity in these patients.

Patients diagnosed with head and neck cancers undergo treatments which include various combinations of surgery, radiation and chemotherapy. These treatments result in short and long-terms side effects and complications that could be life altering for these patients. Body image distress and survivorship challenges in these patients are now being recognized as major challenges these patients face. Additionally, employment challenges and financial toxicity is also a major concern that needs to be highlighted. In this session, we have expert speakers including a head and neck surgeon, a head and neck clinical psychologist, a nurse practitioner and a radiation oncologist. They will be addressing these issues and educating the attendees on these topics.

Potential Challenges/Barriers to Change:

1. Establishing head and neck survivorship programs in hospitals or institutions requires institutional commitment and staff resources. This may not be possible in all programs.
2. Help with post-treatment employment and mitigating financial toxicity is a very complicated and challenging problem faced by both patients and providers.
3. There are very few clinical psychologists who specialize in the care and management of head and neck cancer patients.

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Appreciate the body image distress faced by patients treated for head and neck cancer.
2. Understand the survivorship challenges in head and neck cancer patients.
3. Recognize the financial hardships faced by head and neck cancer patients.

References:

1. Graboyes EM, Kistner-Griffin E, Hill EG, Maurer S, Balliet W, Williams AM, Padgett L, Yan F, Rush A, Johnson B, McLeod T, Dahne J, Ruggiero KJ, Sterba KR. Mechanism underlying a brief cognitive behavioral treatment for head and neck cancer survivors with body image distress. Support Care Cancer. 2023 Dec 16;32(1):32. doi: 10.1007/s00520-023-08248-7. PMID: 38102496.
2. Macias D, Hand BN, Maurer S, Balliet W, Ellis MA, Pipkorn P, Huang AT, Nilsen ML, Ruggiero KJ, Williams AM, Marsh CH, Li H, Rhoten BA, Sterba KR, Graboyes EM. Factors Associated With Risk of Body Image-Related Distress in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1019-1026. doi: 10.1001/jamaoto.2021.1378. PMID: 34236423; PMCID: PMC8267841.
3. Mott NM, Mierzwa ML, Casper KA, Shah JL, Mallen-St Clair J, Ho AS, Zumsteg ZS, Prince MEP, Dossett LA, Chen MM. Financial Hardship in Patients With Head and Neck Cancer. JCO Oncol Pract. 2022 Jun;18(6):e925-e937. doi: 10.1200/OP.21.00683. Epub 2022 Feb 15. PMID: 35167324; PMCID: PMC9797234.

There is a great need for improvement in outcomes for HPV negative HNSCC patients. There are ongoing efforts to better understand the biology of HPV negative HNSCC, and reported and ongoing therapeutic clinical trials to try to improve outcomes in this patient population. It is important to be up to date with subject matter in order to best counsel and treat patients as well as plan future research for these patients.

It is imperative that providers and researchers stay up to date with current practice, understanding and future directions in the treatment of HPV negative HNSCC. This session will provide attendees with the opportunity to gain exposure to the current state of knowledge in understanding the biology of this disease and also understand current management and past and future trials.

Attendees need to determine when and how the latest science and clinical data will affect their day-to-day practice, and thus be able to narrow competency gaps in the understanding of HPV negative HNSCC.

There is a great need for improvement in outcomes for HPV negative HNSCC patients. In this session we will first discuss our current understanding of the biology and tumor immune microenvironment in HPV negative HNSCC, critically important to improving therapeutic efficacy. Subsequently, the talks will be focused on our current management and therapeutic options as well as the latest clinical trials and future directions in the treatment of HPV negative HNSCC, in both the curative intent and recurrent/metastatic setting.

Potential challenges/barriers to change:

1. A lack of exposure to the latest scientific developments in HPV negative HNSCC
2. A lack of exposure to clinical trials conducted in the curative intent setting in HPV negative HNSCC
3. A lack of exposure to clinical trials and standard therapies in the recurrent/metastatic setting for HPV negative HNSCC

Expected results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Have a better understanding of the biology and tumor immune microenvironment in HPV negative HNSCC patents.
2. Have a better understanding of our current treatment options and future directions in the treatment of HPV negative HNSCC in the curative intent setting.
3. Have a better understanding of our current treatment options and future directions in the treatment of HPV negative HNSCC in the recurrent/metastatic setting.

References:

1. NCCN.org
2. PMID 33794205
3. PMID 31679945

Cancer-directed therapy for the management of head and neck cancer results in non-negligible toxicities. There is a high incidence of oral mucositis, other oral complications such as osteoradionecrosis, and swallowing complications. Early identification of toxicity and rapid implementation of appropriate supportive care interventions are necessary to mitigate these side effects, improve oncologic and functional outcomes and quality of life.

It is imperative that health professionals taking care of head and neck cancer patients remain current in the best care practices for management of oral mucositis and other associated oral complications, and have early recognition of potentially immune-mediated dysphagia complications.

This educational activity will focus on the identification and management of oral and swallowing complications caused by cancer-directed therapy for patients with head and neck cancer.

Potential Challenges/Barriers to Change:

1. Lack of knowledge/expertise
2. Lack of resources or multidisciplinary expertise

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Apply best available evidence for management of oral complications caused by cancer-directed therapy for HNSCC by utilizing MASCC/ISOO and ASCO guidelines
2. Recognize devices, drugs and drug mechanisms that are furthest along in trial development for management of oral mucositis
3. Know the 4 fundamentals of Oral Care in head and neck cancer patients
4. Gain access to clinical practice tools to enhance communication with patients and colleagues chairside
5. Identify potential dysphagia complications related to immunotherapy, understand the importance of PROMS and clinical measures to quantify these complications and collaborate closely with the multidisciplinary care team

References:

1. MASCC/ISOO/ASCO guidelines

We are in an era of abundant technological innovation. Numerous emerging tools may allow clinicians to evaluate the status of cancer and make clinical decisions faster and less invasively. Failure to stay informed on the portfolio of emerging technologies risks delaying implementation of helpful new instruments.

It is imperative that head/neck cancer treating physicians understand cutting edge technologies to assist in patient care decision making. 

Potential Challenges/Barriers to Change:

1. Access to research based clinical tool
2. Validation of emerging methods
3. Availability of computer resources

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills.
• When appropriate, apply new strategies and make practice modifications.

Upon completion of this live activity, attendees should be able to do the following:

1. Identify key potential uses of saliva based clinical decision tools
2. Identify key potential uses for plasma based clinical decision tools
3. Identify key potential uses for AI based clinical decision tools

References:

1. https://pubmed.ncbi.nlm.nih.gov/30010779/
2. https://doi.org/10.1373/clinchem.2010.153767
3. https://www.nature.com/articles/s41571-020-0417-8

This session will address the lack of representation of underrepresented minorities in cancer clinical trials.

A lack of diverse representation in cancer clinical trials:

• Reduces patients’ opportunities to access new therapies
• Delays enrollment and thus the efficiency of research
• Limits the generalizability of the results

We are not optimally collecting or reporting data on race and ethnicity and need to learn the minimum standards for collecting this data.

There is an underrepresentation of minorities in head and neck cancer clinical trials, and we need to learn the skills and strategies for equitable representation in clinical trials. This session will help teach the strategies that can be used to overcome structural barriers of segregation of cancer care and restrictive eligibility in trials, unconscious bias, patient awareness and lack of trust.

Carmen Guerra, MD, presents on the persistent racial and ethnic disparities that exist in patient access to clinical trials in head and neck oncology. She will describe the extent of the representation gap and provide examples of successful programs in place that are actively improving the status quo. Participants will leave able to more optimally collect and report on data on race and ethnicity, and with ideas to engage with their local communities to work toward the FDA’s diversity action plan with respect to head and neck oncology.

Potential Challenges/Barriers to Change:

1. Funding for programs to address the FDA’s diversity action plan

Expected Results:

• Give learners an opportunity to increase their level of knowledge and skills
• When appropriate, apply new strategies and make practice modifications

Upon completion of this live activity, attendees should be able to do the following:

1. Improve the accuracy of race and ethnicity data collection in clinical trials.
2. Approach work with communities to partner on clinical trial awareness and recruitment with humility and mutual respect.
3. Use tools described in the lecture to work with home institutions to operationalize aspects of the FDA’s diversity action plan.

References:

1. Sauer AB et al. Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020. JAMA Otolaryngology-Head and Neck Surgery. 2022 148(7):662-669